SABS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	648.00
Average Volume	14 288.00
Market Cap	40.59M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Kropotova Alexandra	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	Sullivan Eddie Joe	Buy	190 000	Employee Stock Option (right to buy)
2024-02-21	Bausch Christoph Lawrence	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	King Michael	Buy	115 000	Employee Stock Option (right to buy)
2024-02-21	Reich Samuel J	Buy	434 000	Employee Stock Option (right to buy)

INSIDER POWER
70.15
Last 88 transactions
Buy: 19 783 333 \| Sell: 3 137 658

SAB Biotherapeutics, Inc. Correlation

10 Most Positive Correlations
SHBI	0.924
RXT	0.912
POTX	0.907
MVST	0.905
WSBC	0.902
VNDA	0.9
BCAB	0.9
SPFI	0.899
OPHC	0.898
UCBI	0.897

10 Most Negative Correlations
RMRM	-0.93
APOP	-0.915
IIN	-0.882
EXFO	-0.881
TIG	-0.874
MLVF	-0.873
AUPH	-0.872
EVCM	-0.871
SUMR	-0.871
CARG	-0.869

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SAB Biotherapeutics, Inc. Financials

Annual	2023
Revenue:	$2.24M
Gross Profit:	$-1.51M (-67.28 %)
EPS:	$-7.64

Q4	2023
Revenue:	$305 011
Gross Profit:	$-639 390 (-209.63 %)
EPS:	$-3.86

Q3	2023
Revenue:	$1.27M
Gross Profit:	$281 915 (22.24 %)
EPS:	$-0.970

Q2	2023
Revenue:	$85 518.00
Gross Profit:	$-806 748 (-943.37 %)
EPS:	$-1.360

Financial Reports:

No articles found.

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.